ASA. V. Serdiuk

A. V. Serdiuk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. V. Serdiuk has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development and internal validation of a stage-specific risk calculator for personalised management and prediction of treatment outcomes in diabetic retinopathy

    by Anton Serdiuk

    Relevance. Diabetic retinopathy (DR) is characterised by significant clinical heterogeneity, which complicates prediction of initial treatment failure manifested by rapid disease progression. Aim. To develop and internally validate a novel, stage-specific prognostic calculator that integrates clinical and instrumental parameters and serum biomarkers of inflammation and endothelial dysfunction to stratify the risk of rapid progression of DR in patients with type 2 diabetes mellitus (T2DM). Materials and methods. A prospective cohort study with 2-year follow-up included 358 patients with T2DM and DR (189 with nonproliferative (NPDR), 96 with preproliferative (PPDR), and 73 with proliferative (PDR) stages). A biomarker subgroup (n = 136) was also evaluated in detail. Logistic regression (marker-by-marker) with false discovery adjustment was used to identify the most significant predictors. Optimal stage-specific thresholds were calculated using the Youden index and validated by bootstrap resampling (500 iterations). Based on this, an interactive two-module (clinical and biomarker) risk calculator was developed. Results. The strongest predictors of the general clinical panel were central retinal thickness and volume according to optical coherence tomography (OCT), clinical maculopathy, HbA1c level and diabetic macular edema. The leading systemic biomarkers were L-selectin (LS), endothelial monocyte-activating polypeptide II (EMAP II), E-selectin (ES), interleukin-1β (IL-1β) and endothelial NO synthase (eNOS). Bootstrap validation confirmed the pronounced stage-dependent effectiveness of the predictors. LS was the most universal marker (optimism-corrected accuracy 0.935, 0.867 and 0.731 for NPDR, PPDR and PDR, respectively). In contrast, EMAP II, IL-1β, and eNOS demonstrated high adjusted specificity (0.915-0.993) for PPDR and PDR, but had limited sensitivity for NPDR. In high-risk groups with PPDR and PDR, the rate of rapid progression was 74-87% for the clinical panel and 94-100% for the biomarker panel despite standard therapy, versus 10-14% and 2-24%, respectively, in low-risk groups with NPDR. Retrospective clinical testing (proof-of-concept) confirmed the ability of the tool to propose a treatment strategy with the lowest historical rate of ineffectiveness based on an integrated patient risk profile. Conclusions. The developed stage-specific calculator integrating OCT metrics and systemic biomarkers provides stratification of the risk of initial treatment failure in DR. The significant stage-dependent variability in prognostic value highlights the need for customised modelling. Despite the high internal stability and practical value for personalised DR management, further external validation in independent cohorts is necessary.

  • Open Access

    Serum L- and E-selectins as independent predictors of the adverse development and course of diabetic retinopathy in type 2 diabetes mellitus

    by A.V. Serdiuk, S.YU. Mogilevskyy, V.M. Serdiuk, M.S. Babenko, S.V. Ziablitsev

    Background. Endothelial activation and leukocyte-endothelium interactions are central to diabetic retinopathy (DR) and may underlie diabetic maculopathy (DMP). Serum markers for macular risk stratification remain limited. Aim of the study was to evaluate serum L- (LS) and E-selectins (ES) as independent predictors of the adverse development and course of diabetic retinopathy in type 2 diabetes mellitus. Materials and methods. Baseline cross-sectional analysis included 136 patients with type 2 diabetes and DR. DMP was assessed as present/absent (+/–); optical coherence tomography endpoints were central retinal thickness (CRT) and volume (CRV). LS and ES were measured by enzyme-linked immunosorbent assay. Linear and logistic regression (per +10 ng/mL) were adjusted for age, diabetes duration, systolic blood pressure, and DR stage; ROC analysis assessed discrimination. Results. DMP was present in 42.6 % of patients (58/136). LS and ES were higher in DMP+ than in DMP– (p < 0.001). After adjustment, both biomarkers were independently associated with higher CRT and CRV (p < 0.001) and predicted DMP (LS: odds ratio 4.14; ES: odds ratio 5.92 per +10 ng/mL; p < 0.001). Discrimination was excellent (AUC 0.900 for LS; 0.902 for ES); optimal cutoffs were LS ≥ 49.0 ng/mL and ES ≥ 55.9 ng/mL. For strictly defined diabetic macular edema, associations attenuated after adjustment for DR stage. Conclusions. LS and ES are strong independent predictors of DMP and worse optical coherence tomography structural outcomes in DR and may support pragmatic risk stratification.

  • Open Access

    Elevated baseline von Willebrand factor levels indicate greater disease severity and predict treatment failure in diabetic retinopathy

    by A.V. Serdiuk, S.YU. Mogilevskyy, M.S. Babenko, S.V. Ziablitsev

    Background. The search for systemic biomarkers capable of reflecting the activity of diabetic retino­pathy (DR) and predicting adverse treatment outcomes is an important clinical task of modern ophthalmology. Of particular interest is von Willebrand factor (vWF), which is a marker of endothelial dysfunction. Therefore, our aim was to evaluate the association of baseline vWF levels with the stage of DR and treatment failure, defined as rapid DR progression within 2 years, as well as to establish its potential prognostic utility in patients with type 2 diabetes mellitus (T2DM). Materials and methods. The study analyzed data from 136 T2DM patients with DR. DR stages were classified according to the WHO criteria as non-proliferative, pre-proliferative, and proliferative DR. The association of vWF with disease progression was assessed using ordinal and binary logistic regression models, adjusted for clinical confounders (age, sex, T2DM duration, glycated hemoglobin (HbA1c), systolic blood pressure, and baseline active ophthalmic treatment). Predictive utility was determined via ROC analysis with repeated stratified 5-fold cross-validation (50 repeats). Results. The presence of treatment failure was observed in 58.1 % of cases. vWF levels consistently increased with DR severity: 16.37 µg/mL in non-proliferative, 30.66 µg/mL in pre-proliferative, and 41.49 µg/mL in proliferative DR (p < 0.001). In treatment failure, vWF levels were significantly higher (34.26 µg/mL) compared to its absence (18.01 µg/mL; p < 0.001). In adjusted models, a 1 µg/mL increase in vWF independently increased the odds of a more severe DR stage (OR 1.23; p < 0.001) and treatment failure (OR 1.19; p < 0.001). The area under the ROC curve was 0.846; an optimal cut-off of 29.37 µg/mL yielded a sensitivity of 64.6 % and a specificity of 93.0 %. Conclusions. Baseline vWF levels demonstrate a consistent association with DR severity and represent a clinically relevant predictor for risk stratification of treatment failure in patients with T2DM.

  • Open Access

    Triglyceride-glucose index as a predictor of severe and rapidly progressive diabetic retinopathy in patients with type 2 diabetes mellitus

    by A.V. Serdiuk

    Background. Proliferative diabetic retinopathy (PDR) and rapid progression of DR in patients with type 2 diabetes mellitus (T2DM) require simple markers for risk stratification. The triglyceride-glucose (TyG) index is a simple and reliable indicator of insulin resistance, which is calculated based on the results of routine laboratory tests. The purpose was to determine the clinical and prognostic significance of the TyG index as a marker of PDR and rapid progression of DR during 2 years of observation, as well as to establish a cut-off value of the TyG index for practical risk stratification in patients with T2DM. Materials and methods. In a prospective cohort study, 357 patients with T2DM and DR were examined. TyG index was calculated as ln[triglycerides×fasting glucose/2]. Associations with endpoints were analyzed by binary logistic regression with adjustment for age, T2DM duration, and systolic blood pressure; the threshold value of TyG was determined by the Youden index. Results. The TyG index was higher in the PDR group (p < 0.001) and in the rapidly progressing DR (p = 0.004), and its increase per unit was associated with a 2.73-fold increase in the odds of PDR (95% confidence interval (CI) 1.45–5.14; p = 0.002) and a 1.89-fold increase in the odds of rapid DR progression (95% CI 1.15–3.10; p = 0.012). The area under the curve was 0.626 for PDR and 0.589 for rapid progression; the optimal TyG threshold was 10.63 and provided a specificity of 82–83 %. Conclusions. The TyG index is an independent marker of severe and rapidly progressive PD in T2DM and can be used as a pragmatic “rule in” criterion as part of multiparametric risk stratification for prioritizing ophthalmological surveillance.

  • Open Access

    Atherogenic dyslipidemia (lipid fractions and simple lipid indices) as a predictor of diabetic macular edema and adverse optical coherence tomography outcomes in diabetic retinopathy

    by A.V. Serdiuk, S.YU. Mogilevskyy, M.S. Babenko, S.V. Ziablitsev

    Background. Diabetic macular edema (DME) is a major vision-threatening manifestation of diabetic retinopathy (DR), whereas pragmatic systemic markers for routine risk stratification are limited. Therefore, our aim was to evaluate associations of lipid fractions and simple lipid indices with DME and optical coherence tomography (OCT) outcomes and to identify practical cutoff values. Materials and methods. A cross-sectional analysis included 358 patients with type 2 diabetes mellitus and DR staged as non-proliferative/pre-proliferative/proliferative (52.8/26.8/20.4 %). DME was assessed as present/absent; OCT endpoints were central retinal thickness and volume. Lipid fractions comprised total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), very-low-density lipoprotein cholesterol (VLDL-C), and triglycerides; indices included non-HDL-C, lipid ratios, and the atherogenic index of plasma. Nonparametric tests, logistic regression with odds ratios (ORs) adjusted for age, diabetes duration, and systolic blood pressure, and receiver operating characteristic analysis with area under the curve were applied. Results. DME prevalence was 19.6 % and increased from 5.8 % in non-proliferative DR to 49.3 % in proliferative DR (p for trend < 0.001). DME was associated with higher OCT metrics (both p < 0.001). In adjusted models, DME was associated with higher total cholesterol (OR 1.62), LDL-C (OR 1.62), VLDL-C (OR 5.32) and non-HDL-C (OR 1.51) per 1 mmol/L, whereas lipid ratios and atherogenic index of plasma were not significant. VLDL-C showed moderate discrimination (area under the curve 0.615; cutoff 1.05 mmol/L). Conclusions. Atherogenic lipid fractions, particularly VLDL-C and non-HDL-C, are linked to DME and worse OCT outcomes and warrant external validation.


  • Open Access

    Модель прогнозу ефективності лікування діабетичної ретинопатії при цукровому діабеті 2-го типу на підставі визначення маркерів ендотеліальної дисфункції

    by С. Ю. Могілевський, A. V. Serdiuk, V. N. Serdiuk, С. В. Зябліцев, S. Yu. Mogilevskyy

    Мета. Розробити прогностичну модель оцінки ефективності лікування діабетичної ретинопатії (ДР) при цукровому діабеті (ЦД) 2-го типу на підставі визначення маркерів ендотеліальної дисфункції.Матеріал та методи. Дослідження виконано як одноцентрове проспективне спостережне когортне з 2-річним періодом спостереження. Обстежено 136 пацієнтів (136 очей) з ЦД 2-го типу та ДР, яких було розподілено на групи: 1-а – з непроліферативною ДР (60 очей), 2-а – з препроліферативною ДР (ППДР; 42 ока) та 3-я – з проліферативною ДР (ПДР; 34 ока). У сироватці крові імуноферментним методом визначали високочутливий С-реактивний протеїн (вч-СРП), едотелін-1, ендотеліальний моноцит-активуючий поліпептид-II (EMAP-II), ендотеліальну NO-синтазу (eNOS), інтерлейкіни (IL-1β і IL-6), а також вміст метаболітів оксиду азоту (NOx). Повторне офтальмологічне обстеження проводили через два роки лікування, яке включало консервативне, лазерну фотокоагуляцію, анти-VEGF, хірургічне (вітректомію) та їх поєднання. Аналіз результатів дослідження проводився в пакеті EZR v.1.54 (Австрія).Результати. У пацієнтів з різними стадіями ДР встановлено поступове збільшення вмісту у крові всіх маркерів ендотеліальної дисфункції в порівнянні з контролем (у 1,9–16,4 раза; p<0,001). Виключення становила eNOS, вміст якої зменшувався (у 1,5–3,7 раза; p0,8) були відмічені у моделях з EMAP-II, вч-СРП і IL-6. Специфічність моделей з вч-СРП, EMAP-II, eNOS і IL-6 перевищувала 85%, але їх чутливість була досить низькою. У багатофакторну модель прогнозування ризику швидкого прогресування ДР увійшли EMAP-II та eNOS, що вказувало на ключове значення цих маркерів для прогнозу ефективності лікування ДР. Модель мала відмінні показники якості AUC=0,92 (95% ВІ 0,86–0,96; чутливість – 81,0%, специфічність – 91,2%).Висновок. Доведений зв’язок маркерів ендотеліальної дисфункції з результатами лікування ДР. Вперше для української популяції побудована модель прогнозу ефективності лікування ДР з виділенням найбільш значущих маркерів ендотеліальної дисфункції – EMAP-II та eNOS.


  • Open Access

    C-reactive protein as a possible diagnostic and prognostic factor of diabetic retinopathy

    by A.V. Serdiuk, S.YU. Mogilevskyy, S.V. Ziablitsev

    Background. Current data show an important role of C-reactive protein (CRP) in the onset and progression of diabetic retinopathy (DR), which necessitated the study of using its serum content as a possible contributing factor. Aim of the study was to determine the content of CRP at different stages of DR and the possibility of using it as a prognostic factor of its progression. Materials and methods. 136 patients with type 2 diabetes mellitus were examined and divided into groups: first — with non-proliferative DR (NPDR; 60 eyes), second — with preproliferative DR (PPDR; 42 eyes) and third — with proliferative DR (PDR; 34 eyes). Patients were examined and treated for 2 years. Serum content (in μg/l) of high-sensitivity (hs) CRP was determined by the enzyme-linked immunosorbent assay. The analysis of the study results was performed in the EZR v.1.54 package (Austria). Results. Patients with type 2 diabetes and DR reported a significant increase in serum hs-CRP compared to individuals without diabetes. In NPDR, it exceeded the control level by 1.9 times, in PPDR — by 3.2 times, in PDR — by 4.9 times (p < 0.001 for all comparisons). The selection of optimal thresholds for multi-class classification by the One-vs-All method with the construction of receiver operating characteristic (ROC) curves determined the cut-off levels of hs-CRP at different stages of DR. Values less than 1977 μg/l were characteristic of the control group. In patients with NPDR, the indicators ranged from 1978 to 3683.5 μg/l, in PPDR — from 3683.6 to 5523 μg/l, and in PDR, they were more than 5523 μg/l. The content of hs-CRP directly correlated with fasting glycemia (r = 0.194), central retinal thickness (r = 0.517) and volume (r = 0.486), glycated hemoglobin (r = 0.774), total cholesterol (r = 0.385), high-density lipoprotein (r = 0.260), low-density lipoprotein (r = 0.361), and very low-density lipoprotein (r = 0.493), as well as triglycerides (r = 0.374). The risk of DR progression after 2 years of observation increased 2.3 times for every 1000 μg/l increase in the hs-CRP blood content (p < 0.001; odds ratio = 2.33; 95% confidence interval (CI) 1.74–3.14). The area under the ROC curve was 0.84 (95% CI 0.77–0.90), the sensitivity of the model was 69.6 % (95% CI 60.7–81.8), specificity — 91.2 % (95% CI 83.7–97.4). Conclusions. The results obtained justify the possibi­lity of using C-reactive protein as a highly informative biomarker for diagnosing the stage of DR and predicting its progression.

  • Open Access

    Endothelin-1 as a biomarker of diabetic retinopathy and a factor in its progression

    by S.Yu. Mogilevskyy, A.V. Serdiuk, S.V. Ziablitsev

    Background. In modern conditions, the development of simple screening programs using available indicators that can be used as biomarkers is highly relevant. Potentially, endothelin-1 (ET-1), which is involved in the mechanisms of early vascular disorders in diabetic retinopathy (DR), can be considered as such. Aim of the study was to determine the content of ET-1 at different stages of DR and the possibility of its use as a diagnostic and prognostic factor of DR progression. Materials and methods. 136 patients with type 2 diabetes mellitus were examined and divided into groups: 1st — non-proliferative (NPDR, 60 eyes), 2nd — preproliferative DR (PPDR; 42 eyes) and 3rd — proliferative DR (PDR; 34 eyes). Patients were examined and treated for 2 years. ET-1 in blood serum was determined by enzyme-linked immunosorbent assay. The results were analyzed in the EZR v. 1.54 package (Austria). Results. In patients with type 2 diabetes and DR, a significant increase in the content of blood ET-1 was found compared to the control group without diabetes. In NPDR, it exceeded the control level by 2.2 times, in PPDR and PDR — by 3.8–4.1 times (p < 0.001). The content of ET-1 in PPDR and PDR did not differ (p > 0.05) but was higher than in NPDR (by 1.7–1.9 times; p < 0.05). Thus, in the development of DR, ET-1 had two peaks — the first one in the NPDR development (the threshold level is above 1.015 pg/ml) and the second one — in the further NPDR progression (more than 2.0 pg/ml; the accuracy of the prediction is 92.5 %). ET-1 content had direct relationships with systolic (r = 0.512) and diastolic pressure (r = 0.432), fasting glycemia (r = 0.187), central retinal thickness (r = 0.491) and volume (r = 0.478), levels of glycated hemoglobin (r = 0.566), total cholesterol (r = 0.352) and its fractions. The risk of DR progression after 2 years of observation increased with increasing ET-1 content (p < 0.001; odds ratio 5.18; 95% confidence interval 2.69–9.98). Conclusions. The obtained results confirmed and specified the possibility of using ET-1 level in the blood as a highly informative biomarker of NPDR and the prognosis of its progression.


  • Open Access

    Risk of ineffective treatment for diabetic retinopathy of different stages and prognostic factors that determine it

    by A.V. Serdiuk, S.YU. Mogilevskyy

    Background. The purpose was to study the effectiveness of diabetic retinopathy (DR) treatment with different methods and to establish prognostic indicators of its failure. Materials and me­thods. A total of 358 patients (358 eyes) with type 2 diabetes were examined and divided into groups: 1 — with non-proliferative DR (NPDR; 189 eyes), 2 — with preproliferative DR (PPDR; 96 eyes) and 3 — with proliferative DR (PDR; 73 eyes). The central retinal thickness and central retinal volume were determined by optical coherence tomography; serum fasting glucose, glycated hemoglobin, cholesterol, high-, low- and very-low-density lipoproteins, triglycerides, fibrinogen — by colorimetric method; coagulation hemostasis parameters were evaluated as well. Patients were followed for 2 years with conservative, laser, surgical treatment and anti-VEGF therapy. The study results were analyzed using the EZR v. 1.54 package (Austria). Results. Conservative treatment was effective in 54.5 % of patients with NPDR. In PPDR and PDR, 98.8 % of patients showed slow or rapid progression of retinopathy after treatment. The independent factors that determined the failure of treatment for NPDR were the patient’s age, diabetes duration, blood cholesterol and glycated hemoglobin levels, as well as activated plasma recalcification time and thrombin time. The independent factors that determined the ineffectiveness of treatment for PPDR and PDR were blood triglycerides, prothrombin time and activated partial thromboplastin time. Conclusions. Lipid metabolism disorders and coagulation homeostasis were powerful factors in the progression of DR and treatment failure. The ineffectiveness of NPDR treatment increased with age and duration of diabetes.


  • Open Access

    PROGNOSTIC MODEL OF THE DIABETIC RETINOPATHY PROGRESSION IN TYPE 2 DIABETES

    by A.V. Serdiuk, S.Y. Mogilevskyy, S.V. Ziablitzev, V.G. Guryanov

    Background. Many prognostic models have been developed to predict diabetic complications, but predicting the progression of diabetic retinopathy (DR) in type 2 diabetes mellitus (T2DM) remains a challenge, as in the early stages of DR there are often no clear ophthalmologic criteria. Aim: develop a prognostic model of diabetic retinopathy progression based on the analysis of clinical data and blood glucose, glycated hemoglobin, and lipid metabolism. Materials and methods. We examined 358 patients (358 eyes) with T2DM and DR, who were divided into groups: Group 1 - with nonproliferative DR (NPDR; 189 eyes), Group 2 - with preproliferative DR (PPDR; 96 eyes) and Group 3 - with proliferative DR (PDD; 73 eyes). Patients were examined using ophthalmologic methods, fasting glucose, glycated hemoglobin (HbA1c), cholesterol, high (HDL), low (LDL) and very low (VLDL) density lipoproteins, triglycerides were determined in the blood serum by colorimetric method. The results of the study were analyzed using the EZR v.1.54 package (Austria). Conclusion. There was no significant difference between the groups in terms of age and duration of T2DM (p>0.05). Blood pressure and HbA1c gradually increased in the groups (p<0.05). The content of cholesterol, lipoprotein fractions and triglycerides in groups 2 and 3 did not differ significantly, but was 1.05-1.19 times higher than in group 1 (p<0.05). A positive effect on the risk of NPDR progression was found in the blood levels of VLDL, HbA1c, LDL, cholesterol, triglycerides, fasting glucose, as well as diastolic and systolic blood pressure (SBP). In a multivariate regression analysis, a 5-factor model of NPDR progression was built, which included age, SBP, and blood levels of HbA1c, LDL-C, and VLDL-C. The model had very good prediction quality (AUC=0.87) and high specificity (91.5%). Thus, predictors of NPDR progression were advanced age, high SBP, and increased blood HbA1c, LDL-C, and VLDL-C. The model can be recommended for confirming a high risk of NPDR progression in questionable clinical cases or as a criterion for evidence-based medical prognosis in appropriate expert systems.